The application of low-dose rivaroxaban in elderly patients with atrial fibrillation.

However, in the multivariable Cox proportional hazards regression model and the competing risk model, the bleeding risk showed a decreasing trend in the low-dose rivaroxaban group, but the difference was not statistically significant (multivariable Cox proportional hazards regression model: HR, 2.16, 95% CI, 0.99 to 4.73; P = 0.0546; competing risk model: HR, 2.01, 95% CI, 0.93 to 4.12; P = 0.0856) ( Table 3 ). 4.

also in 47,180 other papers

In the direct comparison between low-dose rivaroxaban and conventional anticoagulation, we observed a numerical trend toward lower major bleeding risk with the low-dose regimen.

also in 1,012 other papers

We found that in patients aged ≥80 years, rivaroxaban 10 mg was associated with effective prevention of thromboembolic events while showing a favorable trend toward reducing bleeding risk, thereby helping to alleviate clinicians’ concerns regarding bleeding in elderly patients and potentially improving the initiation and maintenance rates of anticoagulant therapy.

also in 1,335 other papers